Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

NCT06093841 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Large B-Cell, Diffuse
Follicular Lymphoma Grade 3B
High-grade B-cell Lymphoma
Mediastinal B-Cell Diffuse Large Cell Lymphoma

Interventions

BIOLOGICAL: Relmacabtagene Autoleucel
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Shanghai Ming Ju Biotechnology Co., Ltd.